abrobo

Shenzhen Institute of Advanced Biomedical Robot Co.,Ltd. is a high-tech medical robotics enterprise founded by a team of experts from the overseas high-level talent introduction program and foreign academicians of the Japan Academy of Engineering. Targeting the industrialization of the significant technological achievements of the cardiovascular intervention surgical robot system under the Ministry of Science and Technology's "863 Program," the company is committed to filling the gap in this field in China. Shenzhen Aibo Medical Robot Co., Ltd. independently develops vascular interventional surgical robot systems, originally proposing technologies such as linear drag-and-push and teleoperation based on multi-source force information fusion, reaching an internationally leading level. Currently, the company’s vascular interventional surgical robot product has been iterated to the fourth generation. In 2017, the team successfully completed human clinical trials at Beijing Tiantan Hospital, becoming the first technical R&D team in this field domestically to complete human clinical trials. The core R&D team of Aibo Medical is composed of masters and doctors who graduated from top universities both domestically and internationally, specializing in biomedical engineering, robotics, control engineering, and related fields.